What is new in melanoma research: Genetics and epidemiology of melanoma in 2003? Review of a workshop held in Milan in May 2003

Melanoma Research

Volumn 14, Issue 2, 2004, Pages 77-84

  Scarrà, Giovanna Bianchi ^a   Testori, Alessandro ^b   Mihm, Martin ^c,d  

^a UNIVERSITY OF GENOA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Detection; Early diagnosis; Epidermiology; Melanoma prevention; Pigmented lesions clinic; Sun protection factor; Sunscreens; Ultraviolet radiation

Indexed keywords

PROTEIN P16; SUNSCREEN;

CORRELATION ANALYSIS; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; EDUCATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; ITALY; MELANOCYTE; MELANOMA; METASTASIS; PHENOTYPE; POPULATION; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 2042475387     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200404000-00001     Document Type: Review

References (26)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC cancer base no. 5. Lyon: IARC Press; 2001.
2. Dennis LK, White E, Lee JAH. Recent cohort trends in malignant melanoma by anatomic site in the United States. Cancer Causes Control 1993; 4:93-100.
3. Bulliard J-L, Cox B, Semenciw R. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969-93. Cancer Causes Control 1999; 10:407-416.
4. SEER cancer incidence public use database. 1973-1998. Bethesda, MD: US Dept. HHS Public Health Service, NCI; 2001.
5. MacKie RM. Incidence, risk factors and prevention of melanoma. Eur J Cancer 1998; 34(Suppl 3):S3-S6.
6. World Health Organization. Intersun. The Global UV Project. Sun protection: simple precautions in the sun. Available at http://www.who.int/peh- uv/ index.html. Accessed September 5, 2002.
7. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer 1998; 78:144-148.
8. Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL et al. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 2000; 67:311-319. Epub 2000 Jun 22.
9. Walker GJ, Gabrielli BG, Castellano M, Hayward NK. Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer 1999; 82:305-312.
10. ARF. J Biol Chem 2001; 276:41424-41434.
11. Auroy S, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarra G, et al. French Hereditary Melanoma Study Group. Sporadic multiple primary melanoma cases: CDKN2A germ-line mutations with a founder effect. Genes Chromosomes Cancer 2001; 32:195-202.
12. Hashemi J, Platz A, Ueno T, Stiemer U, Ringborg U, Hansson J. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 2000; 60:6864-6867.
13. MacKie RM, Andrew N, Lanyon WG, Connor JM. CDKN2A germ-line mutations in UK patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 1998; 111:269-272.
14. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003; 22:3053-3062.
15. Kefford R, Bishop JN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, et al. Melanoma Genetics Consortium Genetic testing for melanoma. Lancet Oncol 2002; 3:653-654.
16. Gillanders E, Hank Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, et al. The Lund Melanoma Study Group; The Melanoma Genetics Consortium Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003, Jul 3 [Epub ahead of print].
17. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970-974.
18. Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumours. Cancer Res 1998; 58:2298-2303.
19. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, et al. A germ-line deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001; 10:55-62.
20. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92:1260-1266.
21. Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, et al. Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999; 83:441-448.
22. Evans HS, Lewis CM, Robinson D, Bell CM, Moller H, Hodgson SV. Cancer risks in women with two breast or ovarian cancers: clues to genetic cancer susceptibility. Int J Cancer 2001; 94:758-759.
23. Dong C, Hemminki K. Multiple primary cancers of the colon, breast and skin (melanoma) as models for polygenic cancers. Int J Cancer 2001; 92:883-887.
24. Hussein MR, Sun M, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, et al. Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog 2002; 34:35-44.
25. Birindelli S, Tragni G, Bartoli C, Ranzani GN, Rilke F, Pierotti MA, et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer 2000; 86:255-261.
26. Chung DC, Rustgi AK. The hereditary non-polyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003; 138:560-570.